Magenta Therapeutics, Inc. (MGTA) News

Magenta Therapeutics, Inc. (MGTA)

Today's Latest Price: $9.20 USD

0.50 (5.75%)

Updated Jul 7 2:17pm

Add MGTA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter MGTA News Items

MGTA News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest MGTA News From Around the Web

Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

NEW YORK, NY / ACCESSWIRE / July 6, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...

Yahoo | July 6, 2020

Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session

Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Yahoo | July 6, 2020

Big DraftKings Investor Bought Up an Embattled Biotech Stock

An Atlas Venture affiliate just paid $10 million for more shares of Magenta Therapeutics. Atlas is also the fourth-largest shareholder in sports-betting company DraftKings.

Yahoo | July 5, 2020

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to the public of $8.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $69.0 million.

Yahoo | June 30, 2020

Magenta Therapeutics prices equity offering at $8

Magenta Therapeutics (MGTA) has priced its public offering of 7.5M common shares at $8.00/share, for expected gross proceeds of $60M.Underwriters' over-allotment is an additional 1,125,000 shares. Closing date is June 29.Previously: Magenta Therapeutics announces $60M equity offering (June 24)...

Seeking Alpha | June 25, 2020

Magenta Therapeutics Announces Pricing of Public Offering

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Magenta also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $60.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Magenta.

Yahoo | June 25, 2020

Magenta Therapeutics announces $60M equity offering

Magenta Therapeutics (MGTA) to offer $60M shares in an underwritten public offering, with underwriters having an option to purchase up to an additional 15% of the shares.Price and number of shares have yet to be decided.The company plans to use the proceeds for clinical development, R&D, working capital and general...

Seeking Alpha | June 24, 2020

Magenta Therapeutics Launches Proposed Public Offering

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Magenta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Magenta.

Yahoo | June 24, 2020

Magenta teams up with Beam Therapeutics in blood disorders

Magenta Therapeutics (MGTA) inks a non-exclusive research and clinical collaboration agreement with Beam Therapeutics (BEAM) to evaluate its antibody-drug conjugate ((ADC)) MGTA-117 for conditioning sickle cell disease and beta-thalassemia patients receiving the latter's base editing therapies.Conditioning is done to prepare a patient receiving edited cells that need to engraft in...

Seeking Alpha | June 15, 2020

Magenta bails on cell therapy in inherited metabolic disorders

Making a "strategic decision," Magenta Therapeutics (MGTA) will discontinue enrollment in a Phase 2 clinical trial evaluating MGTA-456 in patients with inherited metabolic disorders, deciding instead to focus its resources on stem cell mobilization and conditioning programs.It cites COVID-19 disruptions, a growing understanding of the challenges of allogeneic stem cell...

Seeking Alpha | June 11, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5786 seconds.